Katalóg evidencie publikačnej činnosti PU


ID záznamu:PU.Prešov.2013110711382183
Kategória:ADC
Autor:Lizrova Preiningerova Jana (3%)
Autor:Baumhackl Ulf (3%)
Autor:Csepany Tunde (3%)
Autor:Czaplinski Adam (3%)
Autor:Deisenhammer Florian (3%)
Autor:Klímová Eleonóra (3%)
Názov:Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS) [print, elektronický dokument]
Zdroj:CNS neuroscience & therapeutics [print, elektronický dokument]
Lokácia:Roč. 19, č. 5 (2013), s. 302-306
ISSN:1755-5930. - ISSN 1755-5949
Ohlas:[1] 2015. LUGARESI, A. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. In Expert opinion on drug metabolism and toxicology, ISSN 1742-5255. 2015, vol. 11, no. 2, s. 295-306.
Ohlas:[1] 2015. TORO, J., BURBANO, L.E., ZAMORA, A. et al. Teaching case: A man with a progressive gait impairment and visual compromise. In Multiple sclerosis and related disorders, ISSN 2211-0348. 2015, vol. 4, no. 2, s. 176-179.
Ohlas:[1] 2014. BLIGHT, A.R., HENNEY, H.R., COHEN, R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. In Annals of the New York Academy of sciences, ISSN 0077-8923. 2014, vol. 1329, no. 1, s. 33-44.
Ohlas:[1] 2014. SHAH, N.H., AIZENMAN, E. Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and eurodegeneration. In Translation stroke research, ISSN 1868-4483. 2014, vol. 5, no. 1, s. 38-58.
Ohlas:[1] 2015. PAVSIC, K., PELICON, K., LEDINEK, A.H. et al. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients . In Clinical neurology and neurosurgery, ISSN 0303-8467. 2015, vol. 139, s. 35-40.
Ohlas:[1] 2016. UYGUNOGLU, U., GUNDUZ, A., TUTUNCU, M. et al. The effects of dalfampridine on hereditary spastic paraparesis. In European neurology, ISSN 0014-302. 2016, vol. 76, no. 3-4, s. 153.
Ohlas:[1] 2019. FOSCHI, M., LUGARESI, A. Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?. In Expert opinion on pharmacotherapy, ISSN 1465-6566. 2019, vol. 20, no. 11, s. 1309-1320.
Oblasť výskumu:180